Resources from the same session
LBA51 - KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
Presenter: Julie Brahmer
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA52 - EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
Presenter: Ahmet Sezer
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA53 - Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study
Presenter: Fabrice Barlesi
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA54 - Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
Presenter: Jong-Seok Lee
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
LBA55 - WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression
Presenter: Takashi Seto
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA51, LBA52 and LBA53
Presenter: Roy Herbst
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Slides
Webcast
Q&A live discussion
Presenter: Roy S. Herbst
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Webcast
Invited Discussant LBA54 and LBA55
Presenter: Adrian Sacher
Session: Proffered Paper - NSCLC metastatic 2
Resources:
Slides
Webcast